Vena Recognized as a Leader Across All Categories in 2025 Dresner Wisdom of Crowds® EPM Market Study
'This recognition by Dresner Advisory Services reflects our commitment to delivering powerful, intuitive planning solutions that drive agility and resilience for our customers,' said Hugh Cumming, Chief Technology Officer at Vena. 'With our deep Microsoft integrations and AI-powered platform strategy, we're proud to empower FP&A and operations teams with the tools they need to lead through change.'
According to the 2025 report, Vena stands out as best-in-class in areas such as sales professionalism, overall value, technology reliability and ease of upgrade or migration. The company also earned high marks for customization, technical support and integration with third-party technologies—capabilities that underpin Vena's strengths in extended and integrated business planning.
'Vena showed high marks across the board, with key improvements for product, technical support, overall value, and integrity,' said Howard Dresner, Founder and Chief Research Officer at Dresner Advisory Services. 'Ratings in our annual market assessment are driven solely from the voice of the customer, and we congratulate Vena on their excellent performance in this year's study.'
This latest recognition builds on a series of recent honors that highlight Vena's leadership in the market:
Ranked among the top two technological leaders for the second consecutive year in the QKS SPARK Cloud Financial Planning and Analysis 2025 report.
Earned eight Outstanding and Excellent rankings in the 2025–2026 Performance Management Vendor Landscape Matrix (VLM) from BPM Partners, including top ranks in the Budgeting and Planning and Overall Customer Satisfaction categories.
Achieved 55 top or leading rankings in The Planning Survey 25 from BARC.
Recognized as a Niche Player in the 2025 Gartner® Magic Quadrant™ for Financial Close and Consolidation Solutions and a Challenger in the 2024 Gartner® Magic Quadrant™ for Financial Planning Software.
Received TrustRadius Top Rated Award for Fifth Consecutive Year.
To download a copy of the 2025 Dresner Wisdom of Crowds® EPM Market Study, visit here.
About Vena
Vena is the only agentic AI-powered FP&A platform purpose-built to harness the full power of the Microsoft technology ecosystem for finance teams everywhere. Vena amplifies Microsoft's world-leading productivity tools, cloud technology and AI innovation to make FP&A, operational planning and adjacent strategic processes more flexible, efficient and intelligent. Thousands of the world's leading companies rely on Vena to power their planning. For more information, visit venasolutions.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tom's Guide
12 minutes ago
- Tom's Guide
Microsoft Authenticator is going to delete your passwords on Friday — what to do right now
Microsoft Authenticator users who have not yet made plans to switch to a new method are running out of time: The app will stop storing, managing, saving and auto-filling passwords this Friday, August 1. Microsoft has been sending out messages for weeks indicating its plan to move to a passkey method; as of June, users were no longer able to add passwords, and as of July, the autofill function was shuttered. Starting in August, users will be unable to access their saved passwords unless they have ported them over to Microsoft Edge. However, as CNET reports, the passkey method is widely accepted as the next step toward a much more secure option — passwords can be easily guessed via either phishing or brute force, are stored on servers and are often reused or created in an insecure fashion in the first place. Alternatively, passkeys like a fingerprint or facial recognition, are only available on a personal device and don't need to be remembered. Users don't have to use a password manager to keep track of dozens of unique, strong passwords for each account. The Microsoft Authenticator app has been providing secure sign-ins for mobile accounts that require multi-factor authentication, such as push notifications, password-less logins, time-based one-time passwords or biometric-based confirmation. It let users sign into Microsoft accounts using a PIN, facial recognition (such as Windows Hello) or other biometric data like fingerprints. Microsoft's support page explains that saved passwords (not generated password history) are securely synced to your Microsoft account, so users can continue to access them and use the autofill functionality with Edge. Microsoft detailed the switch over instructions for users in a May 1 blog post, stating it would automatically set up users with their best passkey options and make it their default option: Get instant access to breaking news, the hottest reviews, great deals and helpful tips. 'If you have a password and a 'one-time code' set up on your account, we'll prompt you to sign in with your one-time code instead of your password. After you're signed in, you'll be prompted to enroll a passkey. Then the next time you sign in, you'll be prompted to sign in with your passkey.' You can set up a new passkey by opening the authenticator app on your phone, tap on your account, select 'set up a passkey,' then log in with your existing credentials. Once logged in you can set up the passkey. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Business Wire
12 minutes ago
- Business Wire
Gatik Unveils Arena™: Next-Generation Simulation Platform to Accelerate Commercialization of Its Autonomous Trucking Solution, Built on NVIDIA Cosmos
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Gatik, the leader in autonomous freight for regional logistics networks, today announced Gatik Arena™, its next-generation simulation platform designed to accelerate the development and validation of autonomous vehicle (AV) systems. Built in-house and fine-tuned to Gatik's operational and technical needs, Arena™ produces photorealistic, structured, and controllable synthetic data that directly addresses the limitations of traditional real-world data collection. Built in-house and fine-tuned to Gatik's operational and technical needs, Arena™ produces photorealistic, structured, and controllable synthetic data that directly addresses the limitations of traditional real-world data collection. Share As Gatik scales Freight-Only (driverless) operations in 2025, Arena™ will enable safe and efficient training for its autonomous systems on a wide range of driving scenarios - from routine tasks to rare edge cases - reducing reliance on on-road testing and accelerating the safe, cost-effective commercialization of its solution for partners including Kroger (NYSE:KR), Tyson Foods (NYSE:TSN), and Loblaw (TSX:L). To develop this next-generation simulation platform, Gatik is collaborating with NVIDIA to integrate NVIDIA Cosmos World Foundation Models (WFMs), enabling the creation of ultra-high-fidelity, physics-informed digital environments for robust AV training and validation. Capturing rare events in the real world is expensive, time-consuming, and often unsafe. Arena™ addresses this with high-fidelity synthetic data generation - combining real-world logs, trajectory editing, agent modeling, and multi-sensor simulation pipelines to deliver full closed-loop simulations. The result: scalable, safe, and repeatable AV testing in highly realistic digital worlds. 'As the AV industry pushes toward scaled deployments, the bottleneck isn't just better algorithms - it's better, smarter data,' said Gautam Narang, Gatik's CEO and co-founder. 'Arena™ allows us to simulate the edge cases, rare events, and high-risk scenarios that matter most, with photorealism and fidelity that match the complexities of the real world.' 'NVIDIA Cosmos has been purpose-built to accelerate world model training and accelerate physical AI development for autonomous vehicles,' said Norm Marks, Vice President of Global Automotive, NVIDIA. 'Our collaboration with Gatik unlocks the development of safe, reliable, ultra-high-fidelity digital environments for robust AV training and validation, and is helping to accelerate the commercialization of Gatik's autonomous trucking solution at scale.' Solving the Data Bottleneck with Simulation-First Development Traditional fleet testing and data logging cannot provide the scale, diversity, or reproducibility required to validate AV systems comprehensively. Arena™ addresses this challenge through an extensible modular simulation engine that leverages strengths of advanced AI techniques (NeRFs, 3D Gaussian splatting, diffusion models) to enable scaling from quick scenario augmentation to high-fidelity, full-stack simulation - ensuring each component of the autonomy pipeline is trained and validated with the most optimal and resource efficient technique. Photorealistic Neural Rendering: Leveraging neural techniques like volumetric reconstruction to create high-fidelity simulations from abstract representations such as segmentation maps, LiDAR, and HD maps. Scenario Editing and Control: Support for modifying real-world logs - adjusting traffic flow, pedestrians, lighting, and road layouts to conduct controlled A/B testing. Sensor-Accurate Outputs: Multi-modal simulation across camera, LiDAR, and radar to reflect real-world sensor behavior under varied environmental conditions. Closed-Loop Simulation: Real-time interaction between ego-vehicle decisions and surrounding agents (NPCs), enabling testing of the full autonomy stack in complex interactive environments. This includes modeling vehicle dynamics, policy interactions, and latent scene evolution. Structured Synthetic Data Generation: Enables scalable, annotation-free data generation for machine learning workflows, regression testing, and safety case validation. Purpose-Built for Autonomous Driving Arena™ is engineered with AV-specific needs in mind, including support for difficult-to-collect or safety-critical scenarios such as: Adverse Weather & Visibility: Rain, fog, snow, low-light, glare, and occlusion impacting perception. Unpredictable Road Users: Jaywalking pedestrians, weaving cyclists, lane-splitting motorcycles, animals, and erratic drivers. Challenging Road Geometry: Unprotected turns, faded markings, roundabouts, and poorly marked intersections. Dynamic Road Changes: Construction, detours, school zones, emergency vehicles, and temporary traffic shifts. Sensor & Perception Failures: Occluded signs, low-contrast objects, LiDAR noise, reflections, and degraded sensor inputs. Dense Urban Interactions: High-traffic, mixed road users, double parking, and limited maneuvering space. By simulating these scenarios with spatiotemporal consistency and sensor-level realism, Arena™ reduces the need for costly, time-intensive on-road testing. A Strategic Investment in Scalable Safety Arena™ plays a central role in Gatik's broader simulation-first development strategy. It is tightly integrated with the company's autonomy stack and live safety case platform, allowing AV teams to validate behavior, assess system robustness, and close safety assurance gaps with unmatched efficiency. 'With Arena™, we're reimagining simulation not just as a testing tool, but as a core enabler of safe, scalable autonomy,' said Gautam Narang. 'It gives us the control, realism, and flexibility we need to rapidly build confidence in our systems - and do so without compromising safety or time-to-market.' Today's announcement builds on Gatik's ongoing collaboration with NVIDIA. Earlier in 2025, the two companies announced that Gatik will use NVIDIA DRIVE AGX accelerated by the DRIVE Thor system-on-a-chip running the NVIDIA DriveOS automotive operating system in the company's next-generation autonomous trucks. About Gatik Gatik AI Inc., the leader in autonomous freight for regional logistics networks, is revolutionizing B2B supply chains by enabling safe, consistent, high-frequency freight movement. Gatik's AI-Driven Autonomy is transforming regional logistics for Fortune 500 retailers, and in 2021 the company launched the world's first driverless commercial transportation service. Gatik's autonomous trucks are commercially deployed in multiple markets including Texas, Arkansas, Arizona, and Ontario. Gatik partners with industry leaders including Isuzu Motors, NVIDIA, Cummins, Ryder, and Goodyear. Founded in 2017 by veterans of the autonomous technology industry, the company has offices in Mountain View, Dallas-Fort Worth, Phoenix, Bentonville and Toronto. Safe Harbor Statement This press release contains forward-looking statements, including but not limited to, statements regarding future business strategies, plans, objectives, and anticipated performance. These forward-looking statements are based on the current expectations and beliefs of Gatik and are subject to various risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could impact these forward-looking statements include, but are not limited to, changes in market conditions, economic factors, competitive dynamics, regulatory developments, and unforeseen operational challenges. Gatik undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
Business Wire
12 minutes ago
- Business Wire
NeoGenomics Reports Second Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO) (the ' Company '), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. 'In the second quarter clinical revenue increased by 16% driven by sequential improvement in AUP, a record quarter for volumes, and NGS growth of 23%,' said Tony Zook, CEO of NeoGenomics. 'Strength in our Clinical business was largely offset by continuing pressure in pharma revenue that was beyond our initial assumptions, and a delay in our commercial launch of PanTracer™ Liquid Biopsy that impacted our expected NGS revenue.' 'Looking ahead, we believe Neo will continue to perform as a double-digit revenue growth company, poised to capture additional market share,' continued Mr. Zook. 'We are enhancing our R&D efforts to develop new therapy selection and next-gen MRD products. We are also preparing for the commercial launch of PanTracer Liquid Biopsy, continuing to grow our sales team, increasing efficiencies, and pursuing partnerships through business development efforts that will enhance our portfolio and strengthen our community channel. We are confident that Neo will deliver long-term value for our customers, patients, and shareholders.' Second-Quarter Results Consolidated revenue for the second quarter of 2025 was $181 million, an increase of 10% over the same period in 2024 primarily due to higher volume partially offset by lower non-clinical revenue. Average revenue per clinical test ('revenue per test') increased by 2% to $465. This increase reflects higher value tests, including NGS, and strategic reimbursement initiatives. Consolidated gross profit for the second quarter of 2025 was $77 million, an increase of 7% compared to the second quarter of 2024. This increase was primarily due to an increase in revenue partially offset by higher compensation and benefit costs and an increase in supplies expense. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 43%. Adjusted Gross Profit Margin (1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 45%. Operating expenses for the second quarter of 2025 were $125 million, an increase of $30 million, or 32%, compared to the second quarter of 2024. The increase in operating expenses primarily reflect $20.0 million of impairment charges from impairment of assets held for sale related to the planned sale of Trapelo and the InVisionFirst®-Lung intangible asset impairments, as well as $4.4 million in higher compensation and benefit costs. These increases were partially offset by a decrease in restructuring activities due to the completion of restructuring activities in the fourth quarter of 2024. Net loss for the quarter increased $26 million, or 142%, to $45 million compared to net loss of $19 million for the second quarter of 2024. Adjusted EBITDA (1) for the second quarter of 2025 remained relatively flat at positive $10.7 million, compared to positive $10.9 million in the second quarter of 2024. Adjusted Net Loss (1) was $3.6 million compared to Adjusted Net Loss (1) of $4 million in the second quarter of 2024. Cash and cash equivalents and marketable securities totaled $164 million at quarter end. Pathline, LLC Acquisition On April 4, 2025, the Company completed the acquisition of a 100% ownership interest in Pathline, LLC ('Pathline'), a CLIA/CAP/NYS-certified laboratory based in New Jersey. The purchase price consisted of (i) initial cash consideration of $8.0 million, subject to working capital and other adjustments, and (ii) contingent consideration of $1.0 million. The Pathline acquisition aligns with the Company's strategic objective of expanding its presence, capabilities, and offerings in the Northeastern United States. 2025 Financial Guidance (2) The Company again revised its full-year 2025 guidance (2), as previously revised on April 29, 2025. ____________________ Expand (1) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled 'Use of Non-GAAP Financial Measures.' See also the tables reconciling such measures to their closest GAAP equivalent. (2) The Company reserves the right to adjust this guidance at any time. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities and are reminded that the foregoing estimates should not be construed as guarantees of future performance. Expand Conference Call The Company has scheduled a webcast and conference call to discuss its second quarter 2025 results on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 859170. The live webcast may be accessed by visiting the Investor Relations section of our website at A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. We routinely post information that may be important to investors on our website at Forward Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'plan,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding 2025 financial guidance, seasonality impacts, and long-range strategic objectives and initiatives set forth in the Company's long-range plans.. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to assemble and maintain an effective executive team, to continue gaining new customers, offer new types of tests, integrate its acquisitions, manage the effects of seasonality, execute on its long-range strategic priorities, and otherwise implement its business plans, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and filed with the SEC on February 18, 2025, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and on our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, COST OF REVENUE 104,072 92,008 198,861 182,779 GROSS PROFIT 77,258 72,494 150,504 137,963 Operating expenses: General and administrative 71,747 63,328 139,954 129,125 Research and development 9,023 7,886 19,204 15,506 Sales and marketing 24,075 21,677 46,758 41,898 Restructuring charges — 1,544 — 3,942 Impairment charges 20,041 — 20,041 — Total operating expenses 124,886 94,435 225,957 190,471 LOSS FROM OPERATIONS (47,628 ) (21,941 ) (75,453 ) (52,508 ) Interest income (2,263 ) (4,592 ) (5,984 ) (9,426 ) Interest expense 933 1,666 2,551 3,351 Other (income) expense, net (482 ) 2 (547 ) 265 Loss before taxes (45,816 ) (19,017 ) (71,473 ) (46,698 ) Income tax benefit (724 ) (375 ) (458 ) (995 ) NET LOSS $ (45,092 ) $ (18,642 ) $ (71,015 ) $ (45,703 ) NET LOSS PER SHARE Basic $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) Diluted $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) WEIGHTED AVERAGE COMMON SHARES OUTSTANDING Basic 127,949 126,405 127,664 126,257 Diluted 127,949 126,405 127,664 126,257 Expand NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (71,015 ) $ (45,703 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 18,506 19,651 Amortization of intangibles 16,486 16,723 Stock-based compensation 22,968 16,615 Non-cash operating lease expense 3,353 4,793 Amortization of convertible debt discount and debt issue costs 1,233 1,452 Impairment charges 20,041 — Other impairment charges — 333 Other adjustments (340 ) 159 Changes in assets and liabilities, net (16,229 ) (26,046 ) Net cash used in operating activities (4,997 ) (12,023 ) CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from maturities of marketable securities 11,060 40,501 Purchases of property and equipment (10,823 ) (18,663 ) Business acquisition, net of cash acquired (5,991 ) — Net cash (used in) provided by investing activities (5,754 ) 21,838 CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock, net (234 ) 2,782 Repayment of convertible debt (201,250 ) — Net cash (used in) provided by financing activities (201,484 ) 2,782 Net change in cash and cash equivalents, including cash classified within current assets held for sale (212,235 ) 12,597 Less: net change in cash classified within current assets held for sale (54 ) — Net change in cash and cash equivalents (212,289 ) 12,597 Cash and cash equivalents, beginning of period 367,012 342,488 Cash and cash equivalents, end of period $ 154,723 $ 355,085 Expand Use of Non-GAAP Financial Measures In order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company's core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company's core test-level operating results across reporting periods. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Definitions of Non-GAAP Measures Non-GAAP Adjusted EBITDA 'Adjusted EBITDA' is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income, (ii) interest expense, (iii) tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) restructuring charges, (viii) impairment charges, (ix) intellectual property ('IP') litigation costs, and (x) other significant or non-operating (income) or expenses, net. Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin 'Adjusted cost of revenue' is defined by NeoGenomics as cost of revenue before: (i) amortization of acquired intangible assets, and, if applicable in a reporting period, (ii) stock-based compensation expense. 'Adjusted gross profit' is defined by NeoGenomics as total revenue less adjusted cost of revenue. 'Adjusted gross profit margin' is defined by NeoGenomics as adjusted cost of revenue divided by total revenue. Non-GAAP Adjusted Net (Loss) Income 'Adjusted net (loss) income' is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) restructuring charges, (v) impairment charges, (vi) IP litigation costs, and (vii) other significant or non-operating (income) or expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method. Non-GAAP Adjusted Diluted EPS 'Adjusted diluted EPS' is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. ____________________ Expand (1) For the three months ended June 30, 2025, CEO transition costs include executive retention costs. For the six months ended June 30, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three and six months ended June 30, 2024. (2) For the three and six months ended June 30, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. (3) For the three and six months ended June 30, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and impairment of disposal groups held for sale. There were no such costs for the three and six months ended June 30, 2024. (4) For the three and six months ended June 30, 2025 and June 30, 2024, IP litigation costs include legal fees. (5) For the three and six months ended June 30, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three and six months ended June 30, 2025. Expand ____________________ Expand (1) Cost of revenue adjustments for the three months ended June 30, 2025, includes $4.8 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the six months ended June 30, 2025, includes $9.7 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Cost of revenue adjustments for the three months ended June 30, 2024, includes $4.9 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the six months ended June 30, 2024, includes $9.8 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Expand Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and GAAP EPS to Non-GAAP Adjusted EPS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss (GAAP) $ (45,092 ) $ (18,642 ) $ (71,015 ) $ (45,703 ) Adjustments to net loss, net of tax: Amortization of intangibles 8,124 8,361 16,486 16,723 CEO transition costs (1) 637 — 2,831 — Acquisition and integration related expenses (2) 3,204 — 4,376 — Stock-based compensation expense 12,215 8,841 22,968 16,615 Restructuring charges — 1,544 — 3,942 Impairment charges (2) 20,041 — 20,041 — IP litigation costs (3) 4,460 1,962 7,443 6,243 Other significant expenses, net (4) — 2,358 — 3,960 Adjusted net income $ 3,589 $ 4,424 $ 3,130 $ 1,780 Net loss per common share (GAAP) Diluted EPS $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) Adjustments to diluted loss income per share: Amortization of intangibles 0.06 0.07 0.13 0.13 CEO transition costs (1) — — 0.02 — Acquisition and integration related expenses (2) 0.03 — 0.03 — Stock-based compensation expense 0.10 0.07 0.18 0.13 Restructuring charges — 0.01 — 0.03 Impairment charges (3) 0.16 — 0.16 — IP litigation costs (4) 0.03 0.02 0.06 0.05 Other significant expenses, net (5) — 0.02 — 0.03 Rounding and impact of diluted shares in adjusted diluted shares (6) — (0.01 ) — — Adjusted diluted EPS (non-GAAP) $ 0.03 $ 0.03 $ 0.02 $ 0.01 Weighted average shares used in computation of adjusted diluted EPS: Diluted common shares (GAAP) 127,949 126,405 127,664 126,257 Dilutive effect of options, restricted stock, and converted shares (7)(8) — — — — Expand ____________________ Expand (1) For the three months ended June 30, 2025, CEO transition costs include executive retention costs. For the six months ended June 30, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three and six months ended June 30, 2024. (2) For the three and six months ended June 30, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. (3) For the three and six months ended June 30, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and impairment of disposal groups held for sale. There were no such costs for the three and six months ended June 30, 2024. (4) For the three and six months ended June 30, 2025 and June 30, 2024, IP litigation costs include legal fees. (5) For the three and six months ended June 30, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three and six months ended June 30, 2025. (6) This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive or GAAP net (loss) income is positive and adjusted net (loss) income is negative, also compensates for the effects of additional diluted shares included or excluded in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes. (7) In those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. (8) In those periods in which GAAP net (loss) income is positive and adjusted net (loss) income is negative, this adjustment excludes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. Expand Reconciliation of Non-GAAP Financial Guidance to Corresponding GAAP Measures (in thousands, except per share amounts) (unaudited) GAAP net loss in 2025 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share The following table reconciles the Company's 2025 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS: ____________________ Expand (1) This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes. (2) For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. Expand Supplemental Information Clinical Tests Performed and Revenue (unaudited) ____________________ Expand (1) Excludes tests and revenue related to Pathline and non-clinical activity. (2) Excludes tests and revenue related to non-clinical activity. Expand
